Literature DB >> 25040971

MicroRNAs as promising biomarkers for tumor-staging: evaluation of MiR21 MiR155 MiR29a and MiR92a in predicting tumor stage of rectal cancer.

Yun Yang1, Wei Peng, Tian Tang, Lin Xia, Xiao-dong Wang, Bao-feng Duan, Ye Shu.   

Abstract

OBJECTIVE: In this study, tumor-stage predictive abilities of miR21, miR155, miR29a and miR92a were evaluated in rectal cancer (RC).
METHODS: Expression of miR21, miR155, miR29a and miR92a was detected and quantitated in tumor tissue and in adjacent normal tissue from 40 patients by TaqMan MicroRNA assay.
RESULTS: Significant overexpression of miR21, miR155, miR29a and miR92a was observed in RC tissues. While high expression of miR21, miR155 and miR29a in N1-2 and C-D stages presented a potential correlation with N and Duke stages, partial correlation analysis suggested that only miR155 rather than miR21 and miR29a played a greater influencing role. Receiver operating characteristics (ROC) curve analysis showed that miR155 could discriminate N0 from N1-2 with 85.0% sensitivity and 85.0% specificity, N2 from N0-1 with 90.0% sensitivity and 96.7% specificity, and C-D stage from A-B stage with 81.0% sensitivity and 84.2% specificity.
CONCLUSIONS: Increase in expression of miR155 might represent a novel predictor for RC N and Dukes staging.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25040971     DOI: 10.7314/apjcp.2014.15.13.5175

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  13 in total

1.  Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening.

Authors:  Hui Wang; Lei Wang; Zheng Wu; Rong Sun; Haifeng Jin; Jifeng Ma; Lili Liu; Rui Ling; Jun Yi; Ling Wang; Jiefang Bian; Jianghao Chen; Nanlin Li; Shifang Yuan; Jun Yun
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

Review 2.  MicroRNA in rectal cancer.

Authors:  Azadeh Azizian; Jens Gruber; B Michael Ghadimi; Jochen Gaedcke
Journal:  World J Gastrointest Oncol       Date:  2016-05-15

3.  Concomitant Up-Regulation of Hsa- Mir-374 and Down-Regulation of Its Targets, GSK-3β and APC, in Tissue Samples of Colorectal Cancer.

Authors:  Mohammad Reza Bayatiani; Azam Ahmadi; Reza Aghabozorgi; Fatemeh Seif
Journal:  Rep Biochem Mol Biol       Date:  2021-01

4.  Evaluation of microRNA 92a Expression and Its Target Protein Bim in Colorectal Cancer.

Authors:  Ahmed Zaki; Amal Fawzy; Samia Y Akel; H Gamal; Reham A A Elshimy
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

5.  Anti-Warburg effect of rosmarinic acid via miR-155 in gastric cancer cells.

Authors:  Shuai Han; Shaohua Yang; Zhai Cai; Dongyue Pan; Zhou Li; Zonghai Huang; Pusheng Zhang; Huijuan Zhu; Lijun Lei; Weiwei Wang
Journal:  Drug Des Devel Ther       Date:  2015-05-19       Impact factor: 4.162

Review 6.  MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.

Authors:  Lina Cekaite; Peter W Eide; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe
Journal:  Oncotarget       Date:  2016-02-09

Review 7.  MicroRNAs in colorectal carcinoma--from pathogenesis to therapy.

Authors:  Yudan Chi; Dongming Zhou
Journal:  J Exp Clin Cancer Res       Date:  2016-03-10

8.  Rottlerin as a therapeutic approach in psoriasis: Evidence from in vitro and in vivo studies.

Authors:  Min Min; Bing-Xi Yan; Ping Wang; Lilla Landeck; Jia-Qi Chen; Wei Li; Sui-Qing Cai; Min Zheng; Xiao-Yong Man
Journal:  PLoS One       Date:  2017-12-22       Impact factor: 3.240

9.  MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer.

Authors:  Anne Haahr Mellergaard Eriksen; Rikke Fredslund Andersen; Niels Pallisgaard; Flemming Brandt Sørensen; Anders Jakobsen; Torben Frøstrup Hansen
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

10.  Clinical Diagnostic Implications of Body Fluid MiRNA in Oral Squamous Cell Carcinoma: A Meta-Analysis.

Authors:  Xiujuan Tian; Zhiying Chen; Shaomin Shi; Xianwen Wang; Wanli Wang; Ning Li; Jing Wang
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.